Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease.

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Abstract Text:

K Nagao,K Tsuchihashi,N Ura,T Nakata,K Shimamoto,

OBJECTIVE: To investigate an appropriate hematocrit (Hct) for managing renal anemia complicated by angina pectoris at rest. DESIGN: Nonrandomized, retrospective and prospective observational study. SETTING: Sapporo Medical University Hospital, Sapporo, Japan. PATIENTS: Thirty-two anemic patients (aged 62 +/- 10 years, range 40 to 78) with rest angina in end-stage renal failure. INTERVENTIONS: Serial changes of exercise tolerance (estimated metabolic equivalents [METs] on stress electrocardiography produced by improvement of patients' Hct, using recombinant human erythropoietin (rHuEPO). Adverse effects, such as deteriorating systemic hypertension, were investigated with regard to the severity of coronary arteriographic findings (Leaman's score) and cardiac events within a six-month period. MAIN RESULTS: Higher Hct was clearly correlated with better estimated METs: when Hct was less than 20%, MET was 1.4 +/- 0.5; with 20% < or = Hct < 25% 2.1 +/- 1.4; with 25% < or = Hct < 30% 3.1 +/- 1.6; and with 30% < or = Hct < 35% 4.9 +/- 1.1. Patients with cardiac events (elective balloon angioplasty [n = 5], bypass surgery [n = 1], myocardial infarction [n = 2] and hospital death from congestive heart failure [n = 3]) had advanced coronary lesions compared with patients without coronary events (Leaman's score 15.9 +/- 9.3 versus 7.3 +/- 4.4, respectively, P < 0.01) and lower exercise capacity at 25% < or = Ht < 30% (estimated METs 2.4 +/- 1.2 versus 3.9 +/- 1.9, respectively, P < 0.05). Moreover, there was an inverse linear correlation between estimated METs and Leaman's score only when Hct was over 25%. In prospectively examined subjects (n = 16), Hct 35% or greater without systemic hypertension was obtained in only seven (44%), and no additional effect on exercise tolerance was expected when Hct was 35% or greater. CONCLUSIONS: Managing renal anemia with 30% < or = Hct < 35% with rHuEPO is considered an appropriate therapy in patients with end-stage renal failure complicated by rest angina.

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Publishing Authors By Initials

K Nagao,K Tsuchihashi,N Ura,T Nakata,K Shimamoto,

For similar investigative techniques: epidemiologic methods: epidemiologic study characteristics as topic: epidemiologic studies: case-control studies: retrospective studies research abstracts see: investigative techniques: epidemiologic methods: epidemiologic study characteristics as topic: epidemiologic studies: case-control studies: retrospective studies research

PUBMED ID PMID:

MEDLINE DATE:

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Journal Published:

PUBLICATION TYPE: Review

Journal: The Canadian journal of cardiology

VOLUME: 13

Page Numbers: 747-53

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: Aug

YEAR: 1997

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Information

Number of References: 23

LANGUAGE: eng

NlmUniqueID: 8510280

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Keywords Mesh Terms:

KEYWORDS: Retrospective Studies

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Information

Substance Name: Erythropoietin, Recombinant

Registry Number: 0

Grant and Affiliation Information for Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease.

AFFILIATION: Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.

Country: CANADA

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease Related Publications

• A method for analyzing enzyme kinetics with substrate activation and inhibition and its application to the alpha-chymotrypsin-catalyzed hydrolysis of phenyl acetates.
• Anti-androgen TSAA-291. I. Anti-androgenic effects of a new steroid TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives.
• Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease.
• Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy).
• Comparison of long-term clinical outcome after sirolimus-eluting stent implantation in patients with and without hemodialysis.
• Critical role of exposure time to endogenous oxidative stress in hepatocyte apoptosis.
• Cutting secondary chordae and placing dual taut stitches between the anterior mitral fibrous annulus and the heads of each papillary muscle to treat ischemic mitral regurgitation without deteriorating left ventricular function.
• Diagnostic implications of modified treadmill and head-up tilt tests in exercise-related syncope: comparative studies with situational and/or vasovagal syncope.
• Establishment of External Quality Control Program for hs-CRP and Three-Year Follow-Up of the Performance for Precision and Accuracy.
• Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors.
• Hd3a and RFT1 are essential for flowering in rice.
• Hepatic Arterial Infusion Chemotherapy through a Port-Catheter System as Preoperative Initial Therapy in Patients with Advanced Liver Dysfunction due to Synchronous and Unresectable Liver Metastases from Colorectal Cancer.
• Identification of Dynamin as an Interactor of Rice GIGANTEA by Tandem Affinity Purification (TAP).
• Insulin resistance functionally limits endothelium-dependent coronary vasodilation in nondiabetic patients.
• Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection.
• New concept on atherogenesis.
• Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic Peptide concentration or left ventricular function.
• RAR1 and HSP90 Form a Complex with Rac/Rop GTPase and Function in Innate-Immune Responses in Rice.
• Rapid and efficient synthesis of dysiherbaine and analogues to explore structure-activity relationships.
• Regulation of Rice NADPH Oxidase by Binding of Rac GTPase to Its N-Terminal Extension.
• Small interfering RNA (siRNA) targeting of endogenous promoters induces DNA methylation, but not necessarily gene silencing, in rice.
• Soybean germplasm pools in Asia revealed by nuclear SSRs.
• Zoo animals as reservoirs of gram-negative bacteria harboring integrons and antimicrobial resistance genes.
• [ACE inhibitor, ARB, diuretic, alpha1 blocker]
• [Florigen in rice]
• [Idiopathic right ventricle originated ventricular tachycardia]
• [Lifestyle related diseases in elderly]
• [Surgical correction of idiopathic hypertrophic subvalvular stenosis; with special emphasis on the surgical procedure through the left ventricle]
• [Surgical treatment for variant angina]
• alpha-chymotrypsin-catalyzed hydrolysis of phenyl acetate. Large Hammett's rho constant and participation of histidine-acylated intermediate.